Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters? - Top-Institutions - MDSpire

Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?

  • By

  • Cecilia Lina Pugliano

  • Raymond Fueng-Hin Liang

  • Andrea Ruffa

  • Marietta Iacucci

  • Subrata Ghosh

  • August 1, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Research

  • #2

    Mount Sinai Hospital
    Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Translational Medicine

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Clinical Trials

  • #5

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Inflammatory Bowel Disease

Original Source(s)

Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why it matters?

  • by Cecilia Lina Pugliano, Raymond Fueng-Hin Liang, Andrea Ruffa, Marietta Iacucci, Subrata Ghosh

  • August 1, 2025

Related Content

Metabolic and Structural Alterations Linked to Mice's Vulnerability to Primary Echinostoma caproni Infections

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Mortality trends from colorectal pathologies in the United States (1999–2020): a retrospective cohort study using CDC WONDER